Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Virax Biolabs Group Ltd maintains a gross margin of 80.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -160788.25%, while the net margin is -145725.93%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VRAX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, VRAX competes directly with industry leaders such as FRGT and NIVF. With a market capitalization of $2.03M, it holds a leading position in the sector. When comparing efficiency, VRAX's gross margin of 80.04% stands against FRGT's -213.03% and NIVF's 9.20%. Such benchmarking helps identify whether Virax Biolabs Group Ltd is trading at a premium or discount relative to its financial performance.
